Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific shows strong profit growth:

This article was originally published in Clinica

Executive Summary

Boston Scientific has wiped out its first-half loss with net income of $47 million in the third quarter, up 29% on the previous year. In the first nine months net income was $24.3 million compared with $52.6 million a year earlier. Boston's third-quarter sales were 29% higher at $232.8 million and 28% up at $675.8 million in the first nine months. CEO Pete Nicholas says Boston had "excellent results in both vascular and non-vascular businesses". The three acquisitions this autumn - EP Technologies, Meadox Medicals and Heart Technology - will "further improve Boston's strategic position" in less invasive medicine, Mr Nicholas adds.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093827

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel